|
Market Closed -
Nasdaq
01:30:00 15/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 138.36 USD | +0.16% |
|
+3.87% | +12.73% |
| 11/08 | Global drugmakers invest billions to boost US presence | RE |
| 11/08 | Nucleai And Gilead Sciences Advance AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration | CI |
| Market Cap | 17TCr 15TCr 14TCr 13TCr 24TCr 16,40500Cr 24TCr 1,63100Cr 64TCr 8,21500Cr 64TCr 63TCr 27,30000Cr | P/E 2026 * |
-42.3x | P/E 2027 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 19TCr 16TCr 15TCr 14TCr 26TCr 18,00600Cr 27TCr 1,79100Cr 70TCr 9,01700Cr 71TCr 69TCr 29,96400Cr | EV / Sales 2026 * |
6.13x | EV / Sales 2027 * | 5.53x |
| Free-Float |
99.88% | Yield 2026 * |
2.38% | Yield 2027 * | 2.45% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +0.16% | ||
| 1 week | +3.87% | ||
| Current month | +6.26% | ||
| 1 month | +6.40% | ||
| 3 months | +4.77% | ||
| 6 months | -10.72% | ||
| Current year | +12.73% |
| 1 week | 131.61 |  | 138.43 |
| 1 month | 127.61 | | 140.61 |
| Current year | 116.88 | | 157.29 |
| 1 year | 108.46 | | 157.29 |
| 3 years | 62.07 | | 157.29 |
| 5 years | 57.16 | | 157.29 |
| 10 years | 56.56 | | 157.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/08/26 | Fiscal year | EVP Gen Counsel, Legal & Comp | 14,912 | 0.0012% | ||
| 03/08/26 | Sell | Chief Executive Officer | -15,000 | 0.0012% | ||
| 15/07/26 | Sell | Executive/Senior Manager | -3,000 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +3.87% | +16.25% | +73.27% | 17TCr | |
| -2.25% | -0.47% | +72.43% | +119.36% | 1,05200Cr | |
| -0.66% | +0.43% | +49.01% | +50.11% | 63TCr | |
| -0.54% | +1.39% | +21.88% | +63.83% | 44TCr | |
| -1.99% | -3.32% | +41.98% | +34.08% | 35TCr | |
| -1.05% | -2.81% | +24.22% | +34.67% | 29TCr | |
| -2.12% | -3.67% | -1.09% | +3.11% | 24TCr | |
| -0.63% | +1.04% | +43.03% | +59.10% | 22TCr | |
| -1.19% | -3.41% | -9.18% | -52.41% | 20TCr | |
| -0.04% | +0.11% | +6.69% | -25.73% | 15TCr | |
| Average | -0.60% | +0.62% | +26.52% | +35.94% | 37.48TCr | |
| Weighted average by Cap. | -0.09% | +0.40% | +39.90% | +58.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.07TCr 2.65TCr 2.49TCr 2.27TCr 4.26TCr 2,93600Cr 4.33TCr 29TCr 11TCr 1,47000Cr 12TCr 11TCr 4,88600Cr | 3.27TCr 2.82TCr 2.65TCr 2.41TCr 4.54TCr 3,12600Cr 4.61TCr 31TCr 12TCr 1,56600Cr 12TCr 12TCr 5,20300Cr |
| Net income | -427.47Cr -369.21Cr -346.94Cr -315.52Cr -593.21Cr -41TCr -602.99Cr -4.07TCr -1.59TCr -20TCr -1.6TCr -1.57TCr -68TCr | 1.03TCr 887.45Cr 833.93Cr 758.42Cr 1.43TCr 98TCr 1.45TCr 9.77TCr 3.82TCr 49TCr 3.86TCr 3.77TCr 1,63500Cr |
| Net Debt | 1.67TCr 1.45TCr 1.36TCr 1.24TCr 2.32TCr 1,60100Cr 2.36TCr 16TCr 6.23TCr 80TCr 6.29TCr 6.15TCr 2,66500Cr | 912.45Cr 788.09Cr 740.56Cr 673.5Cr 1.27TCr 87TCr 1.29TCr 8.68TCr 3.39TCr 44TCr 3.43TCr 3.35TCr 1,45200Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | $138.36 | +0.16% | 34,07,825 |
| 13/26/13 | $138.14 | +1.67% | 48,97,034 |
| 12/26/12 | $135.87 | +0.07% | 56,83,968 |
| 11/26/11 | $135.77 | +2.04% | 54,93,691 |
| 10/26/10 | $133.06 | -0.11% | 68,33,770 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
Select your edition
All financial news and data tailored to specific country editions
